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Abstract
Standard short course chemotherapy is recommended by the World Health Organization to control tuberculosis worldwide.
However, in settings with high drug resistance, first line standard regimens are linked with high treatment failure. We
evaluated treatment outcomes after standardized chemotherapy with the WHO recommended category II retreatment
regimen in a prison with a high prevalence of drug resistant tuberculosis (TB). A cohort of 233 culture positive TB patients
was followed through smear microscopy, culture, drug susceptibility testing and DNA fingerprinting at baseline, after 3
months and at the end of treatment. Overall 172 patients (74%) became culture negative, while 43 (18%) remained positive
at the end of treatment. Among those 43 cases, 58% of failures were determined to be due to treatment with an inadequate
drug regimen and 42% to either an initial mixed infection or re-infection while under treatment. Overall, drug resistance
amplification during treatment occurred in 3.4% of the patient cohort. This study demonstrates that treatment failure is
linked to initial drug resistance, that amplification of drug resistance occurs, and that mixed infection and re-infection
during standard treatment contribute to treatment failure in confined settings with high prevalence of drug resistance.
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Introduction
The notification of tuberculosis (TB) cases in the Russian
Federation increased by 7.5% per year during the period 1991 to
1999, reaching 85.2 cases per 100,000 population in 1999 [1]. The
deterioration of the general social-economic situation in Russia,
the shrinking of the health budget, and the decline of health
services during the nineties likely contributed to the resurgence in
TB cases [2].
The World Health Organization adopted the DOTS strategy
(Directly Observed Therapy, Short Course) as the standard
approach to address the global TB epidemic in 1993 [3].
However, TB control during the nineties in Russia did not follow
this policy; treatment was not standardized, mass population
screening and diagnosis of TB was performed predominately
through chest radiography and was often not complemented by
bacteriological confirmation. Supply of routine diagnostics and
anti-TB drugs became irregular, leading to stock-outs and the
erratic treatment of patients. The resulting inadequate treatment
of many TB cases likely contributed to the creation of drug
resistant TB. The global WHO drug surveillance program has
revealed a high prevalence of multi drug resistant TB (MDR TB),
defined as resistance to at least isoniazid and rifampicin, in the
former Soviet Union [4]. The fourth anti tuberculosis drug
resistance survey reports MDR TB estimates for the Russian
Federation of 13% among new cases, 48.6% among previously
treated cases and 19.4% among combined cases [5] While MDR
TB is recognized to be a cause of treatment failure, few published
data link drug resistance directly to treatment outcomes. In this
article, we present the results of a prospective cohort of newly
admitted TB patients in which culture and drug susceptibility
testing (DST) was used to document response to the WHO
standard Category II (re-treatment) regimen, 2HREZS/1HREZ/
5HRE, during 8 months and to assess the limits of such therapy in
a setting with a high prevalence of MDR TB. Molecular
genotyping was employed to address the issue of mixed infection
with a susceptible and resistant strain of M. tuberculosis or re-
infection by a new strain as a possible mechanism for treatment
failure. Finally, we established the amplification of resistance in
intermediately resistant strains in those receiving standard TB
chemotherapy.
This study was conducted as part of a long-term plan with
preparations to initiate MDR-TB therapy with second line drugs
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in the Kemerovo prison system through the recognized Green
Light Committee (GLC) mechanism coordinated by WHO [6].
Methods
This study was embedded in the ongoing TB treatment
programme. All clinical procedures, i.e., sputum sample collection
and clinical treatment were performed as part of the routine
procedures in place at that time. Sputum smear analysis, culture
and DST were routinely done in the local laboratory; subcultures
were sent, with the permission of the local health authorities, to the
Mycobacteriology laboratory in Antwerp for DST quality control
and additional Restriction Fragment Length Polymorphism
(RFLP) testing. All patients enrolled in the TB treatment
programme gave verbal consent. Demographic, clinical and
diagnostic information was retrieved prospectively from the
patient clinical file. All data were entered into an unlinked
database without individual patient identifiers and analyzed
anonymously using Epi-info version 6.2. The study protocol was
approved by the local health authorities. At the time the study was
carried out, the MSF ethics review board did not yet exist.
However, review and approval for publication of the data was
obtained retrospectively from the MSF Ethics review board, in
June 2008.
The study took place in the penitentiary hospital in Mariinsk
in Central Siberia. The prison population in the Kemerovo
region was estimated at that time to be nearly 25,000 prisoners
distributed over 22 colonies/prisons. Suspected TB cases
detected in the general prisons were referred to either the
Mariinsk or Novokousnesk TB penitentiary hospital for
diagnosis and treatment. Both penitentiary hospitals, con-
ceived for 750 patients, were overcrowded and housed some
1,500 TB patients each. The conditions were very harsh,
especially during the long winter months, when outside
temperatures may go below minus 40uC and when ventilation
inside was extremely poor. The majority of prisoners were
packed in ‘wards’ of 20 to 30 persons, slept in bunk beds and
had to take turns for a mattress. Because of internal prison
security procedures, patients could not be separated according
to their infection status or drug resistance pattern and infection
control measures were not in place.
Upon arrival to the referral penitentiary hospital, suspected
cases were screened through sputum smear analysis, culture and
fluoroscopy. Fluoroscopy was used in this prison because films for
chest radiography were generally lacking. As many patients had
taken undocumented TB drugs before arrival to Colony 33, none
of them had however received standard four drug Category I
treatment before, and because of the high prevalence of drug
resistance and the lack of second line drugs [7], all patients were
treated immediately with the WHO recommended Category II
(re-treatment) regimen, 2HREZS/1HREZ/5HRE, during 8
months under daily strict direct supervision (H, Isoniazid; R,
Rifampicin; E, Ethambutol; Z, Pyrazinamide; S, Streptomycin).
All drugs were procured outside Russia and had certificates that
guaranteed their quality. Patients also received high energy milk
and biscuits as food supplements.
A cohort of 233 consecutive newly admitted patients diagnosed
with TB through sputum smear and culture that started treatment
between December 1997 and October 1998 were followed until
the end of treatment. In order to free space for the suspected TB
patients waiting to be transferred from the peripheral prisons, all
patients who had completed treatment and had a negative culture
were immediately transferred back to other prisons. Those prisons
were not accessible for the study team and follow up of these
transferred patients was impossible. Relapse cases could therefore
not be captured in this study.
Sputum collection practices and DOTS management were
those used routinely in the hospital. All patients provided sputum
samples for smear microscopy, culture, DST and RFLP analysis at
baseline, after three months, and at the completion of treatment.
Sputum collection was strictly supervised and included observed
mouth rinsing overseen by experienced health staff. Initial cultures
were done in the renovated laboratory of Marrinsk and infection
control procedures to limit the possibility of laboratory cross-
contamination were installed. Subcultures were sent to the
Mycobacteriological Unit of the Institute of Tropical Medicine
in Antwerp, Belgium, for DST quality control and Deoxyribonu-
cleic acid (DNA)-fingerprinting.
Sputum specimens were decontaminated using the modified
Petroff procedure and cultures performed on Lo¨wenstein-
Jensen (LJ) medium. [8]. DST was performed on LJ medium
by the agar proportion method according to Canatti et al. [9].
All strains were tested for susceptibility to R (40 mg/ml), H
(0.2 mg/ml), E (2 mg/ml) and S (4 mg/ml). PZA susceptibility
testing was not done. RFLP analysis using the IS6110 probe
was performed following standard methods for fingerprinting
of M. tuberculosis [10]. Genomic DNA was digested with PvuII,
electrophoretically fractionated, transferred to Hybond-N+
membranes (Amersham) and hybridized with a chemilumins
cent-labeled IS6110 3’probe. RFLP profiles were analyzed by
means of a computer software program (Gelcomar version 4.1;
Applied Maths, Kortrijk, Belgium) using the Dice co-efficient
for similarity calculations and the unweighted pair group
method with arithmetic averages (UPGMA) for clustering [10].
Two isolates were considered different if they showed 3 or
more bands of difference.
Results
Prior to treatment initiation, isolates from 81 of the 233 patients
(34.8%) were susceptible to all four drugs tested (H, R, E, S), 47
(20.2%) were mono drug-resistant, 61 (26.2%) were poly drug-
resistant and 44 (18.9%) were MDR-TB. Overall, any resistance to
H was 56.6%, to S 51.5%, to E 29.1%, while any resistance to R
was 19.3%. Twenty seven patients (11.6%) were mono resistant to
H and one patient was mono resistant to R. (Table 1). Patients
who had received no or less than one month of therapy before the
initiation of category II regimen were more likely to be pan-
susceptible than patients who received prior therapy for one
month or more (RR=1.50; 95% C.I. 1.06–2.12) (Table 1). Also,
the latter group had significantly more MDR TB than the former
(RR=4.16; 95% C. I. 1.70–10.13).
All 233 TB patients were male prisoners, with a median age of
29 years (range 16–66). Seventy three percent of the patients
reported having taken TB drugs before starting Category II
treatment. Seventy five percent of patients had a cavity on
fluoroscopy and the medium body mass index (BMI) was 19.6
(range 13.4–24.8). (Table 2). The HIV status of patients at the time
of TB diagnosis was not independently determined, but the health
authorities reported that none of the patients was HIV positive at
entry into the prison system. Prior to treatment initiation,
demographic and clinical characteristics of the 44 MDR-TB
patients before starting treatment were not significantly different
compared to the 189 non-MDR TB patients in terms of age, time
spent in prison, presence of a cavity on fluoroscopy or BMI.
However, MDR-TB patients had been significantly more
frequently sentenced than other TB patients, 2.3 versus 1.8
condemnations respectively (p = 0.03).
Treatment Outcome of MDR TB
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Of the 233 TB patients who started treatment, 172 (73.8%)
became culture negative at the end of treatment, 43 (18.4%)
remained culture positive, 1 patient died and 17 patients (7.3%)
had treatment interruption because they were released from prison
while still on therapy (Table 3). Excluding patients who
interrupted treatment, 92% of the pan-susceptible TB patients,
91% of the mono drug-resistant, 86% of the poly drug-resistant
and 37% of the MDR-TB cases had a negative culture at the end
of the treatment.
Table 4 compares the DST results of the 43 patients who
remained culture positive at the end of the treatment (T8) with the
DST results at baseline (before the start of treatment, T0) and after
the initial 3 months of treatment (T3). Patients are classified
according to the drug resistance profile before starting treatment
(T0). Table 4 also shows the comparison of the RFLP patterns of
the isolates obtained at baseline (T0) and after treatment
completion (T8) for each patient. Twenty five patients had strains
with identical RFLP patterns before, during and after treatment
and can be considered as not responding to the chemotherapy
regimen they received. Seventeen out of the 25 patients were
already resistant to all 4 drugs before treatment, while the eight
other patients were poly drug-resistant before starting treatment
and acquired resistance to the drugs they were still susceptible to at
the start of treatment. Seven of them acquired drug resistance
during the first three months; one patient had a negative culture at
T3. Amplification occurred in 6 out of the 56 of initial poly drug-
resistant (10.7%) but not MDR-TB patients, excluding the
defaulters.
Seventeen patients had a strain with different RFLP pattern
before and after treatment. Two cases carried a fully susceptible
strain before treatment, became smear and culture negative after
three months of treatment, but had a different strain, one pan-
Table 1. Classification of the patients according to drug resistance profiles against the four first-line tuberculosis drugs (H,E,R and
S) at time of enrolment (T0).
Classification Resistant to ,1 month prior therapy (%) $1 month therapy (%) All (%)
Pan-susceptible 36 (44.4) 45 (29.6) 81 (34.8)
Mono-resistant H 6 (7.4) 21 (13.8) 27 (11.6)
E 1 (1.2) 2 (1.3) 3 (1.3)
R 1 (1.2) 0 (0) 1 (0.4)
S 7 (8.6) 9 (5.9) 16 (6.9)
Subtotal 15 (18.5) 32 (21.1) 47 (20.2)
Poly-resistant* HE 0 (0) 1 (0.6) 1 (0.4)
HS 15 (18.5) 16 (10.5) 31 (13.3)
HES 10 (12.3) 19 (12.5) 29 (12.4)
Subtotal 25 (30.9) 36 (23.7) 61 (26.2)
Multi-resistantu HRS 0 (0 9 (5.9) 9 (3.9)
HERS 5 (6.2) 30 (19.7) 35 (15.0)
Subtotal 5 (6.2) 39 (25.7) 44 (18.9)
Total 81 (100) 152 (100) 233 (100)
N= 233 H, Isoniazid; E, Ethambutol; R, Rifampicin; S, Streptomycin.
*Poly-resistant TB defined as resistance to more than one drug but not H and R together.
uMulti-resistant TB defined as resistance to at least H and R.
doi:10.1371/journal.pone.0007954.t001
Table 2. Socio-demographic and clinical characteristics of patients at enrolment.
MDR n=44 Non MDR n=189 Total n =233 P value
Age in years: median (range) 30 (16–66) 29 (19–58) 29 (16–66) 0.59 1
No. of condemnations: median (range) 2.3 (1–12) 1.8 (1–6) 1.9 (1–12) 0.03 1
Months spent in prison: median (range) 34 (7–60) 28 (3–72) (3–72) 0.06 1
Body mass index* 19.0 (13.4–23.2) 19.7 (15.3–24.8) (13.4–24.8) 0.06 1
Delay in daysu: median (range) 17 (2–58) 18 (4–395) 18 (2–395) 0.62 1
Cavity on fluoroscopy at entry
Yes no. (%) 35 (79.5) 139 (73.5) 174 (74.7)
No no. (%) 9 (2.0) 49 (25.9) 58 (24.9) 0.66 #
Unknown no. (%) 0 1 (0.5) 1 (0.4)
* Body mass index is calculated as the weight in kilograms divided by the square of the height in meters.
u Delay: time in days between admission to Colony 33 and the start of treatment.
1 t-test; # Chi square test.
doi:10.1371/journal.pone.0007954.t002
Treatment Outcome of MDR TB
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susceptible and one mono-resistant to ethambutol, at the end of
the treatment. A third patient with an initial strain resistant to H
and S became culture negative after 3 months of treatment but
had a pan-susceptible strain cultured at the end of treatment. The
14 remaining patients with a different RFLP isolate profile at T0,
(four pan-susceptible, four mono-resistant, two HS resistant and
Table 3. Treatment outcome of the patients at the end of Category II treatment according to their DST profile at start of
treatment.
Total N (%) Culture – N (%) Culture + N (%) Died N (%) Interrupted N (%)
DST profile
Pan-susceptible 81 (34.8) 71 (87.7) 6 (7.4) 0 4 (4.9)
Mono-resistant 47 (20.2) 38 (80.9) 4 (8.5) 0 5 (10.6)
Poly-resistant 61 (26.2) 48 (78.7) 8 (13.1) 0 5 (8.2)
MDR 44 (18.9) 15 (34.1) 25 (56.8) 1 (2.3) 3 (6.8)
Total 233 (100) 172 (73.8) 43 (18.4) 1 (0.5) 17 (7.3)
Pan-susceptible: susceptible to all four drugs H,E,R,S.
Mono-resistant: resistance to one drug.
Poly-resistant: resistant to at least two drugs, simultaneous resistance to H and R excluded.
MDR: Multi-drug resistant: resistance to at least H and R.
doi:10.1371/journal.pone.0007954.t003
Table 4. Drug susceptibility testing results before the start (T0), after 3 months (T3), and at the end of treatment (T8) for patients
remaining culture positive at the end of a full treatment course with comparison of RFLP results at T0 and T8.
No. of
Patients
Resistance
pattern at T0 N
Resistance
pattern at T3 N
Resistance
pattern at T8 Identical RFLP Changed RFLP Interpretation
6 Susceptible 1 Culture – 1 susceptible 1 re-infection or laboratory error
1 Culture – 1 E 1 re-infection or laboratory error
3 Culture – 3 HERS 3 re-infection or mixed infection
1 HES 1 HERS 1 re-infection+ acquired R resist
or mixed infection
1 S 1 Culture – 1 HERS 1 re-infection or mixed infection
3 H 2 Culture – 2 HERS 2 re-infection or mixed infection
1 HERS 1 HERS 1 re-infection or mixed infection
4 HS 1 Culture – 1 Susceptible 1 re-infection or laboratory error
1 Culture – 1 HRS 1 re-infection or mixed infection
1 Culture – 1 HERS 1 re-infection or mixed infection
1 HERS 1 HERS 1 acquired ER resistance
4 HES 3 HERS 3 HERS 3 acquired R resistance
1 Culture – 1 HERS 1 acquired R resistance
4 HRS 3 HERS 3 HERS 3 acquired E resistance
1 HRS 1 HERS 1 re-infection or mixed infection*
21 HERS 9 Culture – 9 HERS 7 treatment failures
1 mixed or re-infection
1 mixed infection1
9 HERS 9 HERS 7 treatment failures
1 mixed infection or re-infectionu
1 mixed or re-infection**
3 n/a 3 HERS 3 treatment failures
43 Total 43 43 25 18 43
Number of patients = 43.
RFLP, Restriction Fragment Length Polymorphism; H, Isoniazid; R, Rifampicin; E, Ethambutol; S, Streptomycin; n/a = not available.
* T0 and T3 isolates identical; T3 and T8 isolates different.
1 Both RFLP profiles were unique.
u Intermediate isolate (T3) showed different RFLP.
** RFLP at T8 not available, but RFLP patterns at T0 and T3 were different.
doi:10.1371/journal.pone.0007954.t004
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four MDR strains) and T8 had a MDR strain at the end of
treatment. For one patient the RFLP pattern at month 8 was not
available; however, the RFLP patterns at T0 and T3 were
different.
Discussion
The result of this study showing a MDR-TB prevalence of 19%
among this inmate cohort in Mariinsk is very high and consistent
with previously published Colony 33 data from 1997 where the
prevalence of MDR TB was 22% [7]. Similarly high levels of
MDR-TB were reported among prisoners in Azerbaijan and
Georgia during the same time period [12,13]. While a history of
inadequate TB treatment may be the original underlying cause of
drug resistance, once MDR-TB is created, it becomes a source of
primary infection and possibly re-infection while under treatment,
especially in an overcrowded, poorly ventilated prison environ-
ment. Transmission of drug-resistant strains has been documented
in other congregate settings such as hospitals and prisons and in
HIV [14,15,16]. Mono resistance to H was more frequent (11.6%)
than mono resistance against R (0.4%). However, since PZA
susceptibility testing was not performed, this gives not the full
picture.
The finding that MDR-TB was positively associated with the
number of condemnations, and thus passage through the pre-trial
centres where prisoners were kept for long periods of time in
extremely overcrowded and harsh living conditions while awaiting
their trial, suggests that MDR-TB strains may have been
transmitted in these pre-trial centres. High rates of TB have been
documented in a pre-trial detention centre in Kemerovo [17]. The
HIV status of the patients was not confirmed independently, but
the fact that no other AIDS related opportunistic infections were
detected and the low case fatality offer assurance that HIV
infection was not a problem.
Seven percent of the 233 patients interrupted therapy because
they were released from prison before their conviction release
date. Although they were referred to public health services to
complete treatment, it is unknown if they continued their
treatment. All other patients, with the exception of the patient
who died, completed their treatment. Adherence was very high,
which may be partly explained by the previous experience patients
had witnessing daily deaths in TB afflicted inmates and by the fact
that the prison inmate leadership strongly supported the Colony
33 DOTS program.
The failure rate among the patients who completed treatment
was 20%. High failure rates of 29% after completion of Category I
or II have also been reported in a prison population in Azerbaijan,
where the MDR TB prevalence was 23% [12]. Treatment success,
i.e., a negative culture at the end of treatment, for pan-susceptible,
mono-resistant and poly-resistant non-MDR patients who com-
pleted treatment can be considered good as they achieved or
surpassed the WHO target of 85%. However, the culture
conversion rate at the end of treatment of 37% for the MDR
TB patients is extremely poor and approaches the spontaneous
cure rate of tuberculosis seen in the pre-chemotherapy days.
Treatment failure was clearly linked to the initial drug resistance
pattern and cannot be ascribed to a lack of treatment supervision,
poor quality drugs or other programmatic problems. The overall
treatment success of 74% based on a negative culture at treatment
completion (T8) should be interpreted cautiously as patient follow
up beyond treatment completion was not feasible. This represents
a limitation of the study and the observed treatment success is most
probably an over-estimate of the eventual outcome since
subsequent TB relapse can not be excluded.
Indeed, Migliori and colleagues reported 28% relapses among
MDR TB patients who had achieved treatment success on
standard short course chemotherapy within a median time to
relapse of 8 months after completion of treatment [18,19].
The resistance amplification rate of 10.7% detected in the
initially poly-resistant patients may be an underestimate since
relapse TB was not captured due to the impossibility to follow up
patients once treatment finished. Several investigators have
reported amplification of resistance to additional agents while
receiving WHO recommended regimens of category I and II [20].
However few reports on amplified drug resistance have been
supported by concurrent RFLP analysis to differentiate resistance
amplification from mixed or re-infection. Cox and colleagues
reported that 17% of poly drug-resistant, but not multidrug-
resistant strains of patients with the same RFLP profile, acquired
additional drug resistance during short-course directly observed
treatment [21]. Unlike the study reported by Cox, drug resistance
testing for pyrazinamide was not done in the current study.
Additional drug resistance was acquired early during the first three
months of therapy, consistent with the findings from the Cox study
[21].
Thirty five percent of the patients with a positive culture at the
end of treatment had a changed RFLP profile. Three patients, two
with an initially fully susceptible strain and one resistant to H and
S, became culture negative after 3 months of treatment but had
either a pan-susceptible strain (two patients) or a strain resistant to
E (one patient), cultured at the end of treatment. These patients
may have been re-infected with a new strain or may represent
episodes of laboratory error, mislabelling or cross-contamination.
The remaining 15 patients with changed RFLP isolate profile
between T0 and T8 were likely re-infected or had mixed
infections. Overcrowding and the extreme living conditions in
this penitentiary hospital together with the lack of infectious
control measures may have favoured re-infection. Such conditions
are however rarely encountered in other non-congregate and
congregate settings. A retrospective analysis of treatment outcomes
in Tomsk [22] found that patients who began treatment in a
hospital setting and who were hospitalized during their treatment
had a substantially higher risk of developing MDR TB than those
who were treated as outpatients. Nosocomial re-infection with a
MDR strain may be a plausible explanation.
However, it is impossible to determine with certainty if a patient
with a different strain at the end of treatment represents an initial
mixed infection, i.e., an infection with two different strains of M.
tuberculosis or a re-infection with another strain during treatment.
This study performed DNA fingerprinting but part of the
attributed re-infections may in fact be initial mixed infections. It
has been shown, using highly specific polymerase chain reaction
(PCR)-based genotyping methods, that in TB patients in a high
incidence setting, the same sputum sample contains different M.
tuberculosis strains [23]. The presence of different M. tuberculosis
strains when analyzing different pre-treatment sputum samples
from the same patient was also demonstrated [24]. Mixed
infections with a drug susceptible and a drug resistant strain at
the beginning of treatment may thus be an alternative explanation
for the observed changes in strains and resistance patterns before
and at the end of treatment. The pre-dominance of the drug
susceptible strains before treatment could be due to a difference of
fitness and growth between the drug susceptible and the drug
resistant strain [25]. The undetected drug-resistant strain could
then have been selected under the pressure of treatment with first
line drugs. [26,27].
Excluding the 3 cases associated with a possible laboratory
error, all patients who remained culture positive at the end of the
Treatment Outcome of MDR TB
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treatment, except one who was still susceptible to E, showed
resistance to all four first-line TB drugs tested. This finding has
important implications for any proposed re-treatment regimen in
settings with high prevalence of drug resistance. Adding a single
drug to a failing regimen or a regimen likely to fail must absolutely
be avoided exception. The high rate of drug resistance found at
baseline before the start of treatment (T0) also raises the question
of what drugs an initial treatment regimen should include in such
settings. These issues have previously been raised elsewhere
[11,12]. Thus, in settings with a high prevalence of drug resistance,
it is mandatory to perform routine DST, not only for all re-
treatment cases but also for newly diagnosed cases, in order to
guide and tailor treatment accordingly and to avoid resistance
amplification and further transmission of resistant strains. For
timely results, rapid culture and PCR based drug resistance testing
methods are needed as drug resistance is acquired early during
treatment.
In conclusion, this study re-confirms the importance of
resistance amplification and the need for DST to guide treatment
in settings with high prevalence of drug resistance. The use of an
inadequate chemotherapy regimen was the cause of treatment
failure (same RFLP profile) in 58% of the patients who remained
culture positive at the end of treatment whereas 42% of the failures
are due to an initial mixed infection or a re-infection (changed
RFLP profile) while being on treatment. A mixed or re-infection is
the reason for treatment failure in all initial pan-susceptible and
mono-resistant TB patients that remained culture positive at the
end of treatment.
Although re-infection has been documented in the case of
recurrent TB in several studies, very few have documented the
possibility of re-infection while on TB therapy. This finding is
mainly important for settings with a high prevalence of MDR TB
and underscores the of the need for adopting comprehensive
measures to prevent re-infection. Specific and strict infection
control measures must be implemented in congregate settings and
especially in prisons with high prevalence of (MDR) TB. In the
wake of the emergence of XDR TB, the current HIV epidemic
and the recommendations of the WHO-convened XDR TB Task
Force in 2006, such measures are of even greater concern. [28].
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